Key result
LMWH replaces UFH for pregnancy VTE due to fewer side effects and easier administration.
Low molecular weight heparins are preferred over unfractionated heparin for managing venous thromboembolism in pregnancy due to better safety and convenience.
Answers are grounded in this paper and cite their sources.
May support LMWH preference for pregnancy VTE; leaves open need for RCTs on dosing and fetal outcomes.
Pulmonary thromboembolism is the leading cause of maternal death in the UK. Optimal management of deep venous thrombosis and pulmonary thromboembolism requires an appreciation of risk factors, particularly thrombophilia, and signs or symptoms suggestive of venous thromboembolism, along with objective diagnosis and treatment with anticoagulants. Low molecular weight heparins are now replacing unfractionated heparin for the treatment of deep venous thrombosis and pulmonary thromboembolism in pregnancy because of the lower risk of side effects, ease of administration and reduced need for monitoring.
No takes yet. Share an insight, caveat, or question.
Ian A. Greer (2001) conducted a review in Venous thromboembolism in pregnancy. Low molecular weight heparins vs. Unfractionated heparin was evaluated. Low molecular weight heparins are replacing unfractionated heparin for treating venous thromboembolism in pregnancy due to a lower risk of side effects, ease of administration, and reduced monitoring.
Synapse has enriched 10 related papers. Consider them for comparative context: